www.idosr.org Ernest
©IDOSR PUBLICATIONS
ISSN: 2550-794X
International Digital Organization for Scientific Research IDOSRJSR10.200000
IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):96-104, 2025.
https://doi.org/10.59298/IDOSRJSR/2024/10.2.96104

Nanomedicine for Targeted Delivery of Antidiabetic Drugs

Ernest Nsubuga

Department of Clinical Pharmacy Kampala International University Uganda
Email: ernest.nsubuga@studwc.kiu.ac.ug

ABSTRACT

Diabetes mellitus remains one of the most pressing global health concerns, with type 1 and type 2 diabetes affecting millions of individuals worldwide. Conventional drug delivery methods often face challenges such as poor bioavailability, systemic side effects, and lack of targeted action, which compromise therapeutic efficacy. Nanomedicine has emerged as a transformative approach in the management of diabetes, offering nanoscale drug delivery systems that improve pharmacokinetics, enhance drug stability, and enable precise targeting to pancreatic β-cells, liver, or adipose tissues. Various nanocarriers, including polymeric nanoparticles, liposomes, dendrimers, micelles, and inorganic nanomaterials, are being investigated for the controlled and site-specific delivery of antidiabetic drugs. This review explores the advances in nanomedicine-based delivery systems, their mechanisms of action, clinical translation, and the potential to revolutionize diabetes management. Emphasis is placed on the design considerations, therapeutic outcomes, safety concerns, and future prospects of nanotechnology in antidiabetic therapy.

Keywords: Nanomedicine, Antidiabetic drugs, Targeted delivery, Diabetes management, Nanocarriers

INTRODUCTION

Diabetes mellitus, a chronic metabolic disorder characterized by persistent hyperglycemia, represents one of the most challenging global health burdens of the 21st century. The disease arises from either autoimmune destruction of pancreatic β-cells leading to insulin deficiency, as in type 1 diabetes, or peripheral insulin resistance with impaired insulin secretion, as in type 2 diabetes[1]. According to the International Diabetes Federation, the global prevalence of diabetes is projected to rise to over 780 million by 2045, underscoring the urgency for more effective therapeutic strategies[2–5]. Traditional drug delivery systems, though widely used, often fall short of addressing the complexity of this disease. Oral hypoglycemic agents suffer from poor bioavailability due to enzymatic degradation and hepatic first-pass metabolism, while insulin injections are invasive and frequently associated with compliance issues[6, 7]. Moreover, systemic drug administration often results in off-target effects, raising the need for more precise delivery methods that can maximize therapeutic efficacy while minimizing side effects.

Nanomedicine offers an innovative solution to these limitations by leveraging nanoscale carriers for drug delivery. Nanoparticles, typically ranging from 1 to 100 nanometers in size, possess unique physicochemical properties that make them ideal for medical applications[8–12]. Their large surface area-to-volume ratio allows efficient drug loading, while surface modification with ligands enables site-specific targeting to key tissues such as pancreatic islets, hepatic cells, or adipocytes. This targeted delivery ensures that therapeutic agents are released precisely where they are needed, reducing systemic toxicity and enhancing clinical outcomes. Additionally, nanocarriers can be engineered for controlled and sustained drug release, thereby reducing dosing frequency and improving patient adherence[13].

One of the central challenges in diabetes management lies in maintaining strict glycemic control to prevent long-term complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy[14]. Current therapeutic approaches ranging from insulin replacement to oral antihyperglycemic drugs like metformin, sulfonylureas, and sodium-glucose co-transporter 2 (SGLT2) inhibitors—do not always provide optimal glycemic stability. The pharmacokinetics of these agents often require frequent administration, and patient compliance is further compromised by the invasive nature of insulin therapy. Nanomedicine has the potential to address these challenges by providing sustained drug release, thereby maintaining plasma drug levels within the therapeutic window for longer durations. For example, polymeric nanoparticles encapsulating insulin can protect the peptide from enzymatic degradation in the gastrointestinal tract, allowing for the development of oral insulin formulations that bypass the need for injections[15–19].

In addition to improving drug stability and bioavailability, nanomedicine enables tissue-specific drug targeting through surface functionalization with targeting ligands[15, 20]. For instance, nanoparticles conjugated with glucose or antibodies can selectively bind to glucose transporter-rich tissues or β-cell surface markers, thereby ensuring that insulin or insulinotropic agents are delivered directly to the pancreas. Similarly, hepatocyte-targeted nanocarriers can improve the efficacy of drugs such as metformin, which exerts its primary action in the liver[17, 21]. This level of precision is not achievable with conventional drug delivery systems. Beyond drug delivery, nanomedicine opens up avenues for multifunctional therapeutic strategies, such as combining drug delivery with real-time glucose monitoring. Nanosensors and nanogels are being developed to respond dynamically to fluctuating glucose levels, releasing insulin in a glucose-responsive manner. This "smart" drug delivery mimics the physiological regulation of glucose by pancreatic β-cells, offering a potential paradigm shift in diabetes management. The integration of nanotechnology into diabetes care could therefore minimize the risk of hypoglycemia, one of the most dangerous side effects of intensive insulin therapy[22].

Despite these promising advances, several challenges must be addressed before nanomedicine can be fully integrated into clinical practice. Safety remains a primary concern, as long-term toxicity, immune responses, and potential bioaccumulation of nanomaterials need thorough evaluation. The scalability and reproducibility of nanoparticle synthesis also present barriers to widespread adoption, as do regulatory hurdles associated with the approval of nanomedicine-based therapies[23]. Nevertheless, the growing body of preclinical and clinical evidence supporting the use of nanomedicine in diabetes highlights its immense potential to revolutionize drug delivery. This review critically examines the role of nanomedicine in the targeted delivery of antidiabetic drugs, beginning with a discussion of the various nanocarriers employed in drug delivery systems. Subsequent sections explore their applications in insulin and oral hypoglycemic drug delivery, clinical translation, safety concerns, and future perspectives. By integrating insights from recent preclinical studies and clinical trials, the review underscores how nanomedicine stands poised to transform diabetes management, making therapy more effective, patient-friendly, and personalized.

Nanocarriers for Antidiabetic Drug Delivery

Nanocarriers represent the backbone of nanomedicine and serve as versatile platforms for delivering antidiabetic drugs. Their primary purpose is to enhance drug solubility, stability, and bioavailability, while simultaneously ensuring controlled release and targeted action. Different types of nanocarriers have been developed, each with unique physicochemical properties that influence their suitability for particular drugs and therapeutic goals.

Polymeric nanoparticles are among the most extensively investigated carriers for antidiabetic drugs. Constructed from biodegradable polymers such as polylactic-co-glycolic acid (PLGA), chitosan, or polycaprolactone, these nanoparticles protect labile drugs like insulin or glucagon-like peptide-1 (GLP-1) agonists from enzymatic degradation[24–26]. Chitosan-based nanoparticles, in particular, exhibit mucoadhesive properties that enhance intestinal absorption, making them excellent candidates for oral delivery of peptide drugs[27, 28]. Additionally, polymeric nanoparticles can be functionalized with ligands to direct them to pancreatic β-cells, allowing site-specific release of therapeutic agents.

Liposomes, spherical vesicles composed of lipid bilayers, offer another promising platform.[29–32] Their amphiphilic nature enables the encapsulation of both hydrophilic and hydrophobic drugs, broadening their applicability to a wide range of antidiabetic agents. Liposomal formulations can enhance the bioavailability of poorly soluble drugs such as thiazolidinediones and provide sustained release of insulin. Surface modification with polyethylene glycol (PEG) or antibodies further prolongs circulation time and improves tissue targeting.

Dendrimers represent highly branched, tree-like macromolecules with numerous surface functional groups. Their unique architecture allows for precise drug conjugation and controlled release profiles. In diabetes therapy, dendrimers can be engineered to deliver insulin or metformin while minimizing systemic toxicity. Their nanoscale size also facilitates penetration through biological barriers, such as the intestinal epithelium, thereby enhancing oral delivery potential[33–35].

Polymeric micelles, formed by the self-assembly of amphiphilic block copolymers, are particularly suitable for the delivery of hydrophobic antidiabetic drugs like pioglitazone. These nanocarriers improve drug solubility, extend systemic circulation, and offer controlled release properties. Targeting moieties such as glucose or peptide ligands can be attached to micelles, allowing selective uptake by tissues with high glucose transporter expression[36–38].

Inorganic nanocarriers, including gold nanoparticles, silica nanoparticles, and zinc oxide nanoparticles, are gaining attention for their multifunctionality. These systems not only act as drug carriers but may also exert intrinsic antidiabetic effects by modulating oxidative stress or enhancing insulin signaling pathways[39]. For example, zinc oxide nanoparticles have been shown to mimic insulin-like activity, offering dual therapeutic benefits when combined with drug delivery. However, concerns regarding long-term toxicity and accumulation in tissues necessitate cautious evaluation[40, 41]. The versatility of nanocarriers lies not only in their ability to carry drugs but also in their capacity to respond to environmental stimuli. Stimuli-responsive nanoparticles, such as pH-sensitive or glucose-responsive systems, are particularly relevant for diabetes management[42]. For instance, nanoparticles that swell and release insulin in response to hyperglycemic conditions mimic the natural feedback mechanisms of β-cells, paving the way for "smart" drug delivery platforms.

In sum, nanocarriers provide a diverse array of strategies for optimizing antidiabetic drug delivery. Their capacity for protection, controlled release, and targeted action makes them superior to conventional drug delivery systems. The choice of nanocarrier depends on the therapeutic agent, route of administration, and desired pharmacological outcome. As the field progresses, the integration of multifunctional and stimuli-responsive designs holds promise for more precise and effective diabetes therapies.

Applications in Insulin Delivery

Insulin replacement remains the cornerstone of therapy for type 1 diabetes and advanced stages of type 2 diabetes. However, conventional insulin administration through subcutaneous injections poses significant limitations, including pain, risk of infection, and poor patient adherence. Nanomedicine offers innovative strategies to overcome these barriers by providing non-invasive, controlled, and targeted insulin delivery systems[43].

One of the most promising applications is the development of oral insulin formulations using nanocarriers. Insulin, being a peptide, is highly susceptible to enzymatic degradation in the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver. Polymeric nanoparticles, particularly those based on chitosan and PLGA, protect insulin from proteolysis and enhance mucosal absorption. Surface modification with PEG or bile acid conjugates further improves intestinal uptake[44]. Studies have demonstrated that oral insulin-loaded nanoparticles can achieve sustained hypoglycemic effects, reducing the need for frequent injections and improving patient compliance. Pulmonary delivery of insulin using nanocarriers is another innovative approach. The lungs provide a large surface area and rich vascularization, allowing rapid absorption of insulin into the systemic circulation[44, 45]. Liposomal and polymeric nanoparticles can be engineered for aerosolized formulations, ensuring stability during nebulization and efficient deposition in the alveolar region. Such systems not only bypass hepatic metabolism but also provide rapid onset of action, closely mimicking physiological insulin secretion[24–26].

Transdermal insulin delivery using nanocarriers is being explored as a painless alternative to injections. Nanoparticles incorporated into microneedle arrays or nanoemulsions facilitate insulin transport across the stratum corneum. These systems offer controlled and sustained release, minimizing glycemic fluctuations and reducing the risk of hypoglycemia. Furthermore, microneedle patches embedded with insulin-loaded nanoparticles allow self-administration and improve convenience[46, 47].

A major innovation in nanomedicine is the development of glucose-responsive insulin delivery systems. These platforms aim to mimic the natural glucose-sensing ability of pancreatic β-cells. Nanoparticles can be engineered with glucose oxidase or phenylboronic acid moieties that respond to elevated glucose concentrations by triggering insulin release. For example, pH-sensitive polymeric nanogels can swell in response to the acidic environment created by glucose oxidation, thereby releasing encapsulated insulin[48]. Such "smart" delivery systems offer the potential for closed-loop diabetes management without the need for continuous glucose monitoring or insulin pumps. In addition to improved convenience, nanomedicine enhances the pharmacokinetics of insulin. Encapsulation in nanoparticles prolongs circulation half-life and reduces renal clearance, ensuring sustained therapeutic levels. Targeted delivery to the liver, the primary site of insulin action, has also been achieved through ligand-functionalized nanoparticles[48]. This hepatocyte-specific delivery more closely replicates physiological insulin distribution, improving metabolic outcomes.

Despite these advances, challenges remain in translating nanotechnology-based insulin delivery into clinical practice. Variability in absorption, manufacturing complexity, and regulatory hurdles must be addressed. Long-term safety data are essential to evaluate potential risks such as immunogenicity and nanoparticle accumulation[49]. Nevertheless, the integration of nanomedicine into insulin therapy represents a paradigm shift, offering the possibility of non-invasive, patient-friendly, and physiologically responsive treatments.

Overall, nanomedicine has demonstrated substantial promise in revolutionizing insulin delivery. By providing oral, pulmonary, transdermal, and glucose-responsive options, nanocarriers hold the potential to enhance patient adherence, reduce complications, and improve long-term glycemic control in diabetes.

Nanomedicine for Oral Hypoglycemic Agents

While insulin therapy is indispensable for type 1 diabetes and advanced type 2 diabetes, oral hypoglycemic agents remain the first-line therapy for most individuals with type 2 diabetes. However, these agents often suffer from poor solubility, instability, and limited bioavailability, leading to suboptimal therapeutic effects. Nanomedicine provides opportunities to overcome these barriers by enhancing the pharmacological performance of commonly prescribed oral drugs[50].

Metformin, the most widely used oral antidiabetic drug, exhibits poor intestinal absorption and requires high doses, often leading to gastrointestinal side effects[51]. Nanoformulations of metformin, including polymeric and lipid-based nanoparticles, improve its solubility and prolong its circulation half-life. Liver-targeted nanoparticles further enhance its efficacy by concentrating the drug at its primary site of action, thereby reducing systemic exposure and associated side effects[51–53].

Sulfonylureas, such as glibenclamide and glipizide, stimulate insulin secretion from pancreatic β-cells but are associated with risks of hypoglycemia. Nanoencapsulation allows controlled release, reducing peak plasma concentrations and minimizing hypoglycemic episodes. Moreover, surface-functionalized nanoparticles can deliver sulfonylureas specifically to β-cells, improving therapeutic precision[54].

Thiazolidinediones, including pioglitazone and rosiglitazone, are peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists that enhance insulin sensitivity. However, their hydrophobicity limits oral absorption. Polymeric micelles and solid lipid nanoparticles improve solubility and bioavailability, while controlled-release formulations mitigate adverse effects such as weight gain and fluid retention[55, 56].

Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin and vildagliptin, prolong the action of incretin hormones, thereby enhancing insulin secretion. Nanoformulations stabilize these drugs against enzymatic degradation and improve their oral bioavailability. Additionally, dual-drug nanoparticles co-delivering DPP-4 inhibitors with insulinotropic peptides provide synergistic effects on glycemic control[57, 58].

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin and empagliflozin, reduce renal glucose reabsorption but are limited by modest bioavailability. Lipid-based nanoparticles improve absorption, while renal-targeted nanocarriers enhance drug accumulation in the kidneys, increasing therapeutic efficacy without systemic toxicity[59].

Beyond enhancing bioavailability, nanocarriers enable multifunctional strategies by co-delivering combinations of oral hypoglycemic drugs. For instance, nanoparticles co-encapsulating metformin and pioglitazone exploit complementary mechanisms—reducing hepatic glucose output and improving insulin sensitivity—while reducing dosing frequency. Such combinatorial delivery systems provide better glycemic control with fewer side effects compared to monotherapy[60].

The potential of nanomedicine also extends to stimuli-responsive oral drug delivery systems. Glucose-sensitive nanoparticles that release sulfonylureas or DPP-4 inhibitors in response to hyperglycemia offer a more physiological approach to therapy. This reduces the risk of hypoglycemia and aligns drug release with the patient's metabolic needs[61]. Although preclinical studies demonstrate promising results, the translation of nanotechnology for oral hypoglycemics faces challenges. Large-scale manufacturing, reproducibility, and cost-effectiveness remain hurdles. Furthermore, long-term safety data are limited, and regulatory approval requires extensive clinical validation. Nonetheless, the integration of nanomedicine into oral hypoglycemic therapy has the potential to enhance efficacy, safety, and patient compliance, ultimately improving outcomes in type 2 diabetes management[62].

Clinical Translation and Challenges

The translation of nanomedicine for antidiabetic drug delivery from laboratory research to clinical practice represents both a promising opportunity and a formidable challenge. Several nanotechnology-based formulations have demonstrated efficacy in preclinical studies, yet relatively few have advanced to clinical trials. This translational gap arises from a combination of biological, technological, and regulatory barriers[63, 64].

One of the major challenges is the complexity of nanoparticle synthesis and scale-up. Laboratory-scale production of nanocarriers often involves sophisticated techniques that are difficult to reproduce on an industrial scale while maintaining uniformity in size, drug loading, and release kinetics[65]. Regulatory authorities require strict quality control, and variability in nanoparticle properties can delay approval processes. Safety concerns also pose a significant hurdle. While nanocarriers are designed to be biocompatible and biodegradable, their long-term interactions with biological systems remain incompletely understood. Potential risks include immunogenicity, oxidative stress, and bioaccumulation in organs such as the liver, spleen, or kidneys[65]. Comprehensive toxicological evaluations are therefore essential. Additionally, inorganic nanocarriers, though effective in some studies, raise concerns about persistence and toxicity, limiting their clinical adoption.

Another obstacle is the regulatory landscape, which is still evolving for nanomedicine. Traditional drug approval frameworks are not fully equipped to evaluate the unique characteristics of nanoscale formulations. Agencies such as the FDA and EMA require extensive preclinical data on pharmacokinetics, biodistribution, and toxicity, which lengthens the development timeline. Furthermore, the high costs of clinical trials and uncertainties surrounding intellectual property rights make pharmaceutical companies cautious about investing in nanomedicine for diabetes.

Future Perspectives

The future of nanomedicine in diabetes management lies in the development of more sophisticated, personalized, and multifunctional systems that go beyond conventional drug delivery. Emerging trends highlight the potential of nanotechnology to not only deliver drugs more effectively but also to integrate diagnosis, monitoring, and therapy into a single platform[66]. One promising direction is the advancement of glucose-responsive "smart" nanocarriers. These systems release insulin or other drugs in response to real-time glucose fluctuations, mimicking the physiological function of pancreatic β-cells. By integrating glucose sensors with nanogels or polymeric nanoparticles, researchers are developing platforms capable of automatic, closed-loop glucose regulation. Such systems could dramatically reduce the burden of frequent monitoring and insulin adjustments, minimizing the risk of hypoglycemia and improving quality of life[66].

Personalized nanomedicine is another emerging frontier. By leveraging patient-specific data, such as genetic profiles, disease progression, and metabolic parameters, nanocarriers can be tailored to optimize therapeutic outcomes[67]. This individualized approach may involve adjusting nanoparticle size, drug loading, or targeting ligands to suit the unique needs of each patient. Integration with digital health technologies, such as wearable glucose monitors and artificial intelligence-driven predictive models, could enable real-time adjustment of therapy, ushering in a new era of precision diabetes care[68]. The concept of nanotheranostics—nanocarriers

that combine therapeutic and diagnostic functions—also holds promise. For example, nanoparticles loaded with antidiabetic drugs and imaging agents could enable simultaneous monitoring of drug delivery and therapeutic response. This dual functionality not only improves treatment efficacy but also facilitates early detection of diabetes-related complications, such as nephropathy or cardiovascular disease[69].

Beyond pharmacological therapy, nanomedicine may play a role in disease-modifying strategies. Stem cell-derived β-cell transplantation and gene therapy are being investigated for curative approaches to diabetes, and nanocarriers can enhance the delivery of genes, proteins, or stem cells to pancreatic tissues[69]. By improving engraftment and survival of transplanted cells, nanomedicine may contribute to regenerative therapies that address the root cause of diabetes rather than merely controlling symptoms. However, realizing these future directions will require overcoming several challenges. Ensuring long-term safety, improving scalability of nanoparticle production, and achieving regulatory approval remain pressing concerns. Ethical considerations surrounding the integration of nanotechnology with digital health and genetic data also need to be addressed[69]. Additionally, the cost of nanomedicine must be balanced against its benefits to ensure equitable access across diverse populations.

Despite these hurdles, the trajectory of nanomedicine in diabetes therapy is undeniably promising. With continued investment in research, interdisciplinary collaboration, and regulatory innovation, nanomedicine has the potential to reshape diabetes management into a more effective, patient-centered, and technologically integrated discipline. Looking ahead, the convergence of nanotechnology with personalized medicine and digital health platforms could herald a transformative shift, moving diabetes care from reactive management to proactive, adaptive, and possibly curative strategies.

CONCLUSION

Despite these challenges, some progress has been made toward clinical translation. Liposomal and polymeric formulations of insulin have entered early-phase clinical trials, demonstrating safety and efficacy in improving glycemic control. Oral insulin nanoparticle systems are being investigated in phase I and II trials, with encouraging results in terms of bioavailability and patient adherence. Similarly, nanoparticle formulations of metformin and thiazolidinediones are under evaluation for enhanced efficacy and reduced side effects. Patient acceptance is another important consideration. While non-invasive delivery systems such as oral, pulmonary, and transdermal nanocarriers offer significant advantages over injections, concerns regarding long-term safety may affect adherence. Transparent communication about the benefits and risks of nanomedicine will be essential to foster trust among patients and healthcare providers. Economic factors also influence clinical translation. Nanoparticle-based formulations are often more expensive to manufacture compared to conventional drugs, raising concerns about affordability and accessibility, especially in low- and middle-income countries where diabetes prevalence is highest. To address this, efforts are underway to develop cost-effective production methods and scalable technologies. In conclusion, while the clinical translation of nanomedicine in diabetes therapy faces significant obstacles, ongoing advances in nanoparticle design, safety evaluation, and regulatory adaptation are gradually bridging the gap between laboratory research and patient care. Continued interdisciplinary collaboration among scientists, clinicians, industry stakeholders, and regulatory agencies will be essential to realize the full potential of nanomedicine in improving diabetes management.

REFERENCES

1. Antar, S.A., Ashour, N.A., Sharaky, M., Khattab, M., Ashour, N.A., Zaid, R.T., Roh, E.J., Elkamhawy, A., Al-Karmalawy, A.A.: Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomedicine & Pharmacotherapy. 168, 115734 (2023). https://doi.org/10.1016/j.biopha.2023.115734
2. Addissouky, T.A., Ali, M.M.A., El Sayed, I.E.T., Wang, Y.: Type 1 diabetes mellitus: retrospect and prospect. Bulletin of the National Research Centre. 48, 42 (2024). https://doi.org/10.1186/s42269-024-01197-z
3. Adhikari, B.: Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. Journal of Chemistry. 2021, 2691525 (2021). https://doi.org/10.1155/2021/2691525
4. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
5. Blagov, A., Nedosugova, L., Kirichenko, T., Sukhorukov, V., Melnichenko, A., Orekhov, A.: Mitochondrial Dysfunction as a Factor of Energy Metabolism Disorders in Type 2 Diabetes Mellitus. FBS. 16, 5 (2024). https://doi.org/10.31083/j.fbs1601005
6. Zhao, R., Lu, Z., Yang, J., Zhang, L., Li, Y., Zhang, X.: Drug Delivery System in the Treatment of Diabetes Mellitus. Front Bioeng Biotechnol. 8, 880 (2020). https://doi.org/10.3389/fbioe.2020.00880
7. Al Tahan, M.A., Al-Khattawi, A., Russell, C.: Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers. Journal of Drug Delivery Science and Technology. 112, 107205 (2025). https://doi.org/10.1016/j.jddst.2025.107205
8. Abbasi, R., Shineh, G., Mobaraki, M., Doughty, S., Tayebi, L.: Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J Nanopart Res. 25, 43 (2023). https://doi.org/10.1007/s11051-023-05690-w

9. Ahmar, H.: Nonenzymatic Electrochemical Detection of Glucose Using Screen-Printed Electrode Modified with Pd–Au Nanoparticles Encapsulated on Dendrimer Grafted Multi-Wall Carbon Nanotubes. Current Applied Sciences. 2, 67–78 (2024). https://doi.org/10.22034/cas.2022.343533.1019
10. Alimohammadvand, S., Kaveh Zenjanab, M., Mashinchian, M., Shayegh, J., Jahanban-Esfahlan, R.: Recent advances in biomimetic cell membrane–camouflaged nanoparticles for cancer therapy. Biomedicine & Pharmacotherapy. 177, 116951 (2024). https://doi.org/10.1016/j.biopha.2024.116951
11. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
12. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discover Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
13. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
14. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
15. Adekiya, T.A., Owoseni, O.: Emerging frontiers in nanomedicine targeted therapy for prostate cancer. Cancer Treatment and Research Communications. 37, 100778 (2023). https://doi.org/10.1016/j.ctarc.2023.100778
16. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. Journal of Nanotheranostics. 6, 21 (2025). https://doi.org/10.3390/jnt6030021
17. Izadiyan, Z., Misran, M., Kalantari, K., Webster, T.J., Kia, P., Basrowi, N.A., Rasouli, E., Shameli, K.: Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine. Int J Nanomedicine. 20, 1213–1262 (2025). https://doi.org/10.2147/IJN.S488961
18. Gannot, I.: A multimodal nanoparticles-based theranostic method and system. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 14, e1796 (2022). https://doi.org/10.1002/wnan.1796
19. Hu, D., Yang, R., Wang, G., Li, H., Fan, X., Liang, G.: Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells. IJN. Volume 19, 2773–2791 (2024). https://doi.org/10.2147/IJN.S445101
20. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int J Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
21. Jiang, Y., Wang, C., Zu, C., Rong, X., Yu, Q., Jiang, J.: Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects. IJN. 19, 9459–9486 (2024). https://doi.org/10.2147/IJN.S466396
22. Behzadifar, S., Barras, A., Plaisance, V., Pawlowski, V., Szunerits, S., Abderrahmani, A., Boukherroub, R.: Polymer-Based Nanostructures for Pancreatic Beta-Cell Imaging and Non-Invasive Treatment of Diabetes. Pharmaceutics. 15, 1215 (2023). https://doi.org/10.3390/pharmaceutics15041215
23. Fortune, A., Aime, A., Raymond, D., Kumar, S.: Nanotechnology in medicine: a double-edged sword for health outcomes. Health Nanotechnology. 1, 9 (2025). https://doi.org/10.1186/s44301-025-00008-2
24. Austria, E., Bilek, M., Varamini, P., Akhavan, B.: Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy. Nano Today. 60, 102552 (2025). https://doi.org/10.1016/j.nantod.2024.102552
25. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials (Basel). 10, 1403 (2020). https://doi.org/10.3390/nano10071403
26. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results in Chemistry. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
27. Cheng, B., Gao, F., Maissy, E., Xu, P.: Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles. Acta Biomater. 84, 378–390 (2019). https://doi.org/10.1016/j.actbio.2018.12.010
28. Imam, S.S., Alshehri, S., Ghoneim, M.M., Zafar, A., Alsaidan, O.A., Alruwaili, N.K., Gilani, S.J., Rizwanullah, M.: Recent Advancement in Chitosan-Based Nanoparticles for Improved Oral

Bioavailability and Bioactivity of Phytochemicals: Challenges and Perspectives. Polymers. 13, 4036 (2021). https://doi.org/10.3390/polym13224036
29. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv Pharm Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
30. Lombardo, D., Kiselev, M.A.: Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application. Pharmaceutics. 14, 543 (2022). https://doi.org/10.3390/pharmaceutics14030543
31. Peter, S., Khwaza, V., Alven, S., Naki, T., Aderibigbe, B.A.: PEGylated Nanoliposomes Encapsulated with Anticancer Drugs for Breast and Prostate Cancer Therapy: An Update. Pharmaceutics. 17, 190 (2025). https://doi.org/10.3390/pharmaceutics17020190
32. Rao, L., Zhu, P., Guo, M., Hu, M., Guo, X., Du, Y., Xu, G.: Nebulized inhalation of nintedanib-loaded biomimetic nano-liposomes attenuated bleomycin-induced interstitial lung fibrosis in mice. Nano Today. 56, 102298 (2024). https://doi.org/10.1016/j.nantod.2024.102298
33. Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J.E.N., Hamblin, M.R.: PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 12, 177–190 (2018). https://doi.org/10.1016/j.apmt.2018.05.002
34. Alamos-Musre, S., Beltrán-Chacana, D., Moyano, J., Márquez-Miranda, V., Duarte, Y., Miranda-Rojas, S., Olguín, Y., Fuentes, J.A., González-Nilo, D., Otero, M.C.: From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications. Pharmaceutics. 17, 927 (2025). https://doi.org/10.3390/pharmaceutics17070927
35. Pérez-Ferreiro, M., M. Abelairas, A., Criado, A., Gómez, I.J., Mosquera, J.: Dendrimers: Exploring Their Wide Structural Variety and Applications. Polymers. 15, 4369 (2023). https://doi.org/10.3390/polym15224369
36. Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantù, L., Nicoli, S.: Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. Journal of Controlled Release. 332, 312–336 (2021). https://doi.org/10.1016/j.jconrel.2021.02.031
37. Guzmán Rodríguez, A., Sablón Carrazana, M., Rodríguez Tanty, C., Malessy, M.J.A., Fuentes, G., Cruz, L.J.: Smart Polymeric Micelles for Anticancer Hydrophobic Drugs. Cancers (Basel). 15, 4 (2022). https://doi.org/10.3390/cancers15010004
38. Junnuthula, V., Kolimi, P., Nyavanandi, D., Sampathi, S., Vora, L.K., Dyawanapelly, S.: Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations. Pharmaceutics. 14, 1860 (2022). https://doi.org/10.3390/pharmaceutics14091860
39. Ajnai, G., Cheng, C.-C., Kan, T.-C., Lu, J.-W., Rahayu, S., Chiu, A., Chang, J.: Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers. Pharmaceutics. 14, 847 (2022). https://doi.org/10.3390/pharmaceutics14040847
40. Kusuma, S.A.F., Harmonis, J.A., Pratiwi, R., Hasanah, A.N.: Gold Nanoparticle-Based Colorimetric Sensors: Properties and Application in Detection of Heavy Metals and Biological Molecules. Sensors (Basel). 23, 8172 (2023). https://doi.org/10.3390/s23198172
41. Ardekani, L.S., Thulstrup, P.W.: Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins. Nanomaterials (Basel). 12, 1456 (2022). https://doi.org/10.3390/nano12091456
42. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J Control Release. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050
43. Liu, C., De Roza, J., Ooi, C.W., Mathew, B.K., Elya, Tang, W.E.: Impact of patients' beliefs about insulin on acceptance and adherence to insulin therapy: a qualitative study in primary care. BMC Primary Care. 23, 15 (2022). https://doi.org/10.1186/s12875-022-01627-9
44. Li, Y., Zhang, W., Zhao, R., Zhang, X.: Advances in oral peptide drug nanoparticles for diabetes mellitus treatment. Bioact Mater. 15, 392–408 (2022). https://doi.org/10.1016/j.bioactmat.2022.02.025
45. Ding, B., Zhu, Z., Guo, C., Li, J., Gan, Y., Yu, M.: Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives. Acta Pharm Sin B. 14, 2006–2025 (2024). https://doi.org/10.1016/j.apsb.2024.02.019
46. Guo, Z., Zhang, Y., Zhao, M., Zhang, W., Li, X., Zhou, F., Peng, H., Wang, Q., Chen, Z.: Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics. Materials Today Bio. 34, 102220 (2025). https://doi.org/10.1016/j.mtbio.2025.102220
47. Qu, F., Geng, R., Liu, Y., Zhu, J.: Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment. Theranostics. 12, 3372–3406 (2022). https://doi.org/10.7150/thno.69999
48. Zhao, L., Wang, L., Zhang, Y., Xiao, S., Bi, F., Zhao, J., Gai, G., Ding, J.: Glucose Oxidase-Based Glucose-Sensitive Drug Delivery for Diabetes Treatment. Polymers (Basel). 9, 255 (2017). https://doi.org/10.3390/polym9070255

49. Pang, H., Chen, Z., Han, F.Y.: Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery. Acta Biomaterialia. 201, 101–120 (2025). https://doi.org/10.1016/j.actbio.2025.06.016
50. Naeem, M.H., Raza, M., Aziz, M.B., Ullah, N., Wahab, A., Khan, Z.A., Farooq, H., Naeem, M.H., Raza, M., Aziz, M.B., Ullah, N., Wahab, A., Khan, Z.A., Farooq, H.: Effectiveness of Insulin Versus Oral Agents in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Retrospective Comparative Study. Cureus. 17, (2025). https://doi.org/10.7759/cureus.90196
51. Dyatlova, N., Tobarran, N.V., Kannan, L., North, R., Wills, B.K.: Metformin-Associated Lactic Acidosis (MALA). In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
52. Basheer, H.A., Salman, N.M., Abdullah, R.M., Elsalem, L., Afarinkia, K.: Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes. Translational Oncology. 53, 102323 (2025). https://doi.org/10.1016/j.tranon.2025.102323
53. Drzewoski, J., Hanefeld, M.: The Current and Potential Therapeutic Use of Metformin—The Good Old Drug. Pharmaceuticals. 14, 122 (2021). https://doi.org/10.3390/ph14020122
54. Li, X.-T., Yun, M.-Z.: The impact of sulfonylureas on diverse ion channels: an alternative explanation for the antidiabetic actions. Front. Cell Dev. Biol. 13, (2025). https://doi.org/10.3389/fcell.2025.1528369
55. Giglio, R.V., Papanas, N., Rizvi, A.A., Ciaccio, M., Patti, A.M., Ilias, I., Pantea Stoian, A., Sahebkar, A., Janez, A., Rizzo, M.: An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina. 58, 1475 (2022). https://doi.org/10.3390/medicina58101475
56. Liu, C.-H., Lee, T.-H., Lin, Y.-S., Sung, P.-S., Wei, Y.-C., Li, Y.-R.: Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. Cardiovascular Diabetology. 19, 2 (2020). https://doi.org/10.1186/s12933-019-0979-x
57. Kasina, S.V.S.K., Baradhi, K.M.: Dipeptidyl Peptidase IV (DPP IV) Inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
58. Rathish, D., Jayasumana, C., Agampodi, S.: Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka. Journal of Health, Population and Nutrition. 38, 3 (2019). https://doi.org/10.1186/s41043-019-0160-x
59. Padda, I.S., Mahtani, A.U., Parmar, M.: Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
60. Souto, E.B., Souto, S.B., Campos, J.R., Severino, P., Pashirova, T.N., Zakharova, L.Y., Silva, A.M., Durazzo, A., Lucarini, M., Izzo, A.A., Santini, A.: Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. Molecules. 24, 4209 (2019). https://doi.org/10.3390/molecules24234209
61. Yu, J., Zhang, Y., Bomba, H., Gu, Z.: Stimuli-responsive delivery of therapeutics for diabetes treatment. Bioeng Transl Med. 1, 323–337 (2016). https://doi.org/10.1002/btm2.10036
62. Li, Z., Luo, B., Chen, Y., Wang, L., Liu, Y., Jia, J., Chen, M., Yang, S., Shi, H., Dai, L., Huang, L., Wang, C., Liu, J.: Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy. Materials Today Bio. 33, 102054 (2025). https://doi.org/10.1016/j.mtbio.2025.102054
63. Din, F. ud, Aman, W., Ullah, I., Qureshi, O.S., Mustapha, O., Shafique, S., Zeb, A.: Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 12, 7291–7309 (2017). https://doi.org/10.2147/IJN.S146315
64. El-Hammadi, M.M., Arias, J.L.: Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials (Basel). 12, 354 (2022). https://doi.org/10.3390/nano12030354
65. Karnwal, A., Jassim, A.Y., Mohammed, A.A., Sharma, V., Al-Tawaha, A.R.M.S., Sivanesan, I.: Nanotechnology for Healthcare: Plant-Derived Nanoparticles in Disease Treatment and Regenerative Medicine. Pharmaceuticals. 17, 1711 (2024). https://doi.org/10.3390/ph17121711
66. Vallianou, N.G., Dalamaga, M., Pavlou, A., Rebelos, E., Karamanolis, N.N., Papachristoforou, E., Mavrothalassitis, E., Eleftheriadou, I., Tentolouris, N., Kounatidis, D.: The Transformative Role of Nanotechnology in the Management of Diabetes Mellitus: Insights from Current Research. Biomolecules. 15, 653 (2025). https://doi.org/10.3390/biom15050653
67. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J Pers Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
68. Vora, L.K., Gholap, A.D., Jetha, K., Thakur, R.R.S., Solanki, H.K., Chavda, V.P.: Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 15, 1916 (2023). https://doi.org/10.3390/pharmaceutics15071916
69. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., Vale, N.: Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 16, 332 (2024). https://doi.org/10.3390/pharmaceutics16030332

CITE AS: Ernest Nsubuga (2025). Nanomedicine for Targeted Delivery of Antidiabetic Drugs. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(2):96-104.
https://doi.org/10.59298/IDOSRJSR/2024/10.2.96104